<DOC>
	<DOC>NCT02072330</DOC>
	<brief_summary>The objective of this study is to compare the efficacy and safety of combined administration of TAK-536CCB (Fix-dose combination of Azilsartan and Amlodipine) and Hydrochlorothiazide (HCTZ) with those of TAK-536CCB in patients with Grade I or II essential hypertension.</brief_summary>
	<brief_title>Study to Evaluate the Efficacy and Safety of Combined Administration of TAK-536CCB and Hydrochlorothiazide in Patients With Grade I or II Essential Hypertension.</brief_title>
	<detailed_description>This study is a randomized, double-blind, multicenter, phase 2/3 study to evaluate the efficacy and safety of combined administration of TAK-536CCB and Hydrochlorothiazide (HCTZ) with those of TAK-536CCB or Hydrochlorothiazide in patients with grade I or II essential hypertension. This study consists of a 4-week single-blind placebo run-in period and a 10-week double-blind treatment period.</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>1. Grade I or II essential hypertension. 2. An office sitting systolic blood pressure of ≥ 150 and &lt; 180 mmHg, and an office sitting diastolic blood pressure of ≥ 95 and &lt; 110 mmHg during the placebo runin period at Week −2 and Week 0. 3. Male or female aged 20 years or older at the time of providing informed consent. 4. Outpatient. 1. Secondary hypertension, grade III hypertension or malignant hypertension. 2. An office sitting systolic blood pressure of ≥160 mmHg or sitting diastolic blood pressure of ≥100 mmHg recorded while on combined therapy with 3 or more antihypertensives within 4 weeks prior to the initiation of the placebo runin period and at Week −4. 3 Evident white coat hypertension or white coat phenomenon. 4. Daynight reversed lifestyle, such as nighttime workers. 5. Sleep apnea syndrome requiring treatment. 6. Have any of the cardiovascular disease or symptoms listed below: Heart disease: myocardial infarction (within 24 weeks before the placebo runin period), coronary arterial revascularization (within 24 weeks before the placebo runin period), severe valvular disease, atrial fibrillation, or following diseases which require medication: angina pectoris, congested heart failure, or arrhythmia. Cerebrovascular disease: cerebral infarction, cerebral hemorrhage (within 24 weeks before the placebo runin period), or transient ischemic attack (within 24 weeks before the placebo runin period). Vascular diseases: peripheral arterial disease with intermittent claudication, artery dissection, aneurysm Advanced hypertensive retinopathy: bleeding, exudation, or papilledema (within 24 weeks before the placebo runin period). 7. Clinically significant hepatic disorder. 8. Clinically significant renal impairment. 9. Significantly low or high Potassium or Sodium levels. 10. Complicated by gout, or had a past history of gout within 24 weeks prior to the initiation of the placebo runin period, or complicated by hyperuricemia requiring medication. 11. Diabetic subject on insulin treatment or poorly controlled type 2 diabetes mellitus. 12. Have a malignant tumor.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Hypertension, Drug therapy</keyword>
</DOC>